SKIN vs. MDXG, KMTS, INMD, IRMD, EMBC, TNDM, AXGN, BBNX, SIBN, and BVS
Should you be buying Beauty Health stock or one of its competitors? The main competitors of Beauty Health include MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), InMode (INMD), iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), Beta Bionics (BBNX), SiBone (SIBN), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.
Beauty Health vs. Its Competitors
Beauty Health (NASDAQ:SKIN) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
Beauty Health has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.
MiMedx Group has higher revenue and earnings than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
MiMedx Group has a net margin of 8.84% compared to Beauty Health's net margin of -6.13%. MiMedx Group's return on equity of 23.03% beat Beauty Health's return on equity.
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Beauty Health had 16 more articles in the media than MiMedx Group. MarketBeat recorded 21 mentions for Beauty Health and 5 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.48 beat Beauty Health's score of 0.86 indicating that MiMedx Group is being referred to more favorably in the news media.
Beauty Health presently has a consensus price target of $2.63, indicating a potential upside of 28.68%. MiMedx Group has a consensus price target of $12.00, indicating a potential upside of 67.13%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Beauty Health.
Summary
MiMedx Group beats Beauty Health on 13 of the 16 factors compared between the two stocks.
Get Beauty Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKIN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SKIN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beauty Health Competitors List
Related Companies and Tools
This page (NASDAQ:SKIN) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access